Hans J. Moebius

1.6k total citations · 1 hit paper
19 papers, 637 citations indexed

About

Hans J. Moebius is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Hans J. Moebius has authored 19 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 6 papers in Psychiatry and Mental health and 5 papers in Molecular Biology. Recurrent topics in Hans J. Moebius's work include Alzheimer's disease research and treatments (8 papers), Dementia and Cognitive Impairment Research (6 papers) and Cholinesterase and Neurodegenerative Diseases (5 papers). Hans J. Moebius is often cited by papers focused on Alzheimer's disease research and treatments (8 papers), Dementia and Cognitive Impairment Research (6 papers) and Cholinesterase and Neurodegenerative Diseases (5 papers). Hans J. Moebius collaborates with scholars based in United States, United Kingdom and Denmark. Hans J. Moebius's co-authors include Gordon Wilcock, Serge Gauthier, Giovanni B. Frisoni, Howard Feldman, Kohkan Shamsi, Charles S. Davis, Luc Bracoud, Lon S. Schneider, B. Schelter and Charles R. Harrington and has published in prestigious journals such as The Lancet, Neurology and Stroke.

In The Last Decade

Hans J. Moebius

18 papers receiving 616 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

2016 321 citations Serge Gauthier, Howard Feldman et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hans J. Moebius United States	7	286	223	185	133	124	19	637
Danira Bažadona Croatia	5	444 1.6×	266 1.2×	186 1.0×	144 1.1×	154 1.2×	10	779
Martina Zvěřová Czechia	12	234 0.8×	201 0.9×	105 0.6×	78 0.6×	116 0.9×	17	643
Karan Govindpani New Zealand	8	323 1.1×	211 0.9×	95 0.5×	168 1.3×	187 1.5×	10	635
Natalia M. Lyra e Silva Canada	8	346 1.2×	198 0.9×	81 0.4×	155 1.2×	116 0.9×	9	677
Luís E. Santos Brazil	14	311 1.1×	184 0.8×	101 0.5×	167 1.3×	148 1.2×	24	689
Ana C. Pereira United States	12	315 1.1×	174 0.8×	70 0.4×	139 1.0×	253 2.0×	22	714
Debbi Ann Morrissette United States	11	159 0.6×	150 0.7×	139 0.8×	77 0.6×	172 1.4×	23	704
Felipe C. Ribeiro Brazil	9	358 1.3×	156 0.7×	74 0.4×	138 1.0×	110 0.9×	13	517
Chitra Vinnakota New Zealand	7	278 1.0×	158 0.7×	69 0.4×	150 1.1×	138 1.1×	12	537
Holly C. Hunsberger United States	13	290 1.0×	120 0.5×	99 0.5×	107 0.8×	255 2.1×	26	566

Countries citing papers authored by Hans J. Moebius

Since Specialization

Citations

This map shows the geographic impact of Hans J. Moebius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Moebius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Moebius more than expected).

Fields of papers citing papers by Hans J. Moebius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans J. Moebius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Moebius. The network helps show where Hans J. Moebius may publish in the future.

Co-authorship network of co-authors of Hans J. Moebius

This figure shows the co-authorship network connecting the top 25 collaborators of Hans J. Moebius. A scholar is included among the top collaborators of Hans J. Moebius based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans J. Moebius. Hans J. Moebius is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Miller, David S., Daniel R. Bateman, Jeffrey L. Cummings, et al.. (2025). Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders. International Psychogeriatrics. 37(5). 100074–100074.

Berthiaume, Andrée‐Anne, et al.. (2024). ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS. Frontiers in Neuroscience. 18. 1348157–1348157. 1 indexed citations

Berthiaume, Andrée‐Anne, et al.. (2024). Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. Neurotherapeutics. 21(4). e00350–e00350. 3 indexed citations

Jack, Clifford R., Ana Graf, Samantha C. Burnham, et al.. (2024). Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(4). e70013–e70013. 3 indexed citations

Moebius, Hans J., et al.. (2023). The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators. Journal of Alzheimer s Disease. 92(1). 1–12. 5 indexed citations

Moebius, Hans J., et al.. (2023). Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating With Composite Clinical Score of Cognition and Function in Alzheimer’s Disease (S26.008). Neurology. 100(17_supplement_2). 3 indexed citations

Moebius, Hans J., et al.. (2023). Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease. Alzheimer s & Dementia. 19(S15). 1 indexed citations

Moebius, Hans J., Charles Bernick, Paul Winner, et al.. (2022). ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial. Alzheimer s & Dementia. 18(S10). 3 indexed citations

Taylor, Robert W., et al.. (2022). Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 20(2). 431–451. 13 indexed citations

10.

Olichney, John, et al.. (2022). Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential. Neural Plasticity. 2022. 1–13. 18 indexed citations

11.

O’Gorman, Cullen, Rita Khoury, Ariana Anderson, et al.. (2020). A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's disease: Recommendations of the ISCTM Working Group. The Journal of Prevention of Alzheimer s Disease. 7(4). 274–282. 6 indexed citations

12.

Gauthier, Serge, Howard Feldman, Lon S. Schneider, et al.. (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet. 388(10062). 2873–2884. 321 indexed citations breakdown →

13.

Keefe, Richard S.E., Nancy Dgetluck, Maria S. Gawryl, et al.. (2015). Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacology. 40(13). 3053–3060. 120 indexed citations

14.

Urfer, Roman, Hans J. Moebius, David Školoudík, et al.. (2014). Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke. Stroke. 45(11). 3304–3310. 73 indexed citations

15.

Harrison, John, Nancy Dgetluck, Maria S. Gawryl, Hans J. Moebius, & Dana Hilt. (2013). P3–285: Validation of a novel cognitive composite assessment for mild and prodromal Alzheimer's disease. Alzheimer s & Dementia. 9(4S_Part_16). 5 indexed citations

16.

Hilt, Dana, Maria S. Gawryl, Gerhard Koenig, Nancy Dgetluck, & Hans J. Moebius. (2012). O4‐12‐04: EVP‐6124, a selective alpha‐7 partial agonist, has positive effects on cognition and clinical function in mild‐to‐moderate Alzheimer's disease patients: Results of a six‐month, double‐blind, placebo controlled, dose ranging study. Alzheimer s & Dementia. 8(4S_Part_20). 4 indexed citations

17.

Suckfüll, M., Michael Althaus, Barbara Ellers‐Lenz, et al.. (2011). A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus. PubMed. 11(1). 1–1. 39 indexed citations

18.

Moebius, Hans J., ‌Barry Reisberg, F.A. Schmitt, & Rachelle S. Doody. (2003). P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease. European Neuropsychopharmacology. 13. S388–S389. 4 indexed citations

19.

Wilcock, Gordon, et al.. (2000). Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. European Neuropsychopharmacology. 10. 360–360. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact